Enhancement of cisplatin sensitivity by NSC109268 in budding yeast and human cancer cells is associated with inhibition of S-phase progression

Cancer Chemotherapy and Pharmacology
Dilip JainWolfram Siede

Abstract

NSC109268 has been described previously as inhibitor of proteasomal degradation and of phosphatase 2Calpha. In a yeast screen, we isolated NSC109268 as an agent altering sensitivity to DNA-damaging agents. We found that NSC109268 and the related compound NSC109272 enhance cellular sensitivity to cis- and transplatin but reduce sensitivity to nitrogen mustard. We explored if similar effects could be found in human cancer cells and if cell cycle analysis could hint at the underlying molecular mechanism. Haploid yeast cells were treated in suspension with platinum agents and nitrogen mustard alone or in combination with NSC compounds, and survival was measured by colony-formation assays. Sensitivity of ovarian and prostate cancer cells toward these treatments was evaluated using the MTS assay. Cell cycle progression was determined by flow cytometry. The enhancement of cisplatin sensitivity by NSC109268 found in yeast was confirmed in cisplatin-sensitive and cisplatin-resistant human ovarian cancer lines and in prostate cancer cells. In yeast and in human carcinoma cells, a correlation of enhanced sensitivity with delaying S-phase progression was revealed. The known activities of NSC109268 as proteasome or phosphatase inhibitor cou...Continue Reading

References

Jan 1, 1991·Cancer Chemotherapy and Pharmacology·M Jäckel, P Köpf-Maier
Oct 9, 2002·Proceedings of the National Academy of Sciences of the United States of America·Seiko IshidaIra Herskowitz
Oct 23, 2002·Molecular Pharmacology·Xinjian LinStephen B Howell
Feb 27, 2003·Proceedings of the National Academy of Sciences of the United States of America·Jerzy Majka, Peter M J Burgers
Apr 2, 2003·Molecular Cell·Christophe LeroyMarie-Claude Marsolier-Kergoat
Jul 2, 2003·Nature Reviews. Cancer·Roshan Agarwal, Stan B Kaye
Aug 28, 2003·Molecular Microbiology·Agnieszka PodlaskaEwa Sledziewska-Gojska
Oct 12, 2004·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Alison K HolzerStephen B Howell
Jan 13, 2006·Annual Review of Pharmacology and Toxicology·Peter M Voorhees, Robert Z Orlowski
Mar 3, 2006·Journal of Medicinal Chemistry·Jessica P RogersPaul Greengard
May 30, 2006·Molecular Cancer Therapeutics·Martina OliveroMaria Flavia Di Renzo
Nov 17, 2006·Cancer Research·Alison K Holzer, Stephen B Howell
Nov 28, 2006·Frontiers in Bioscience : a Journal and Virtual Library·Kenyon G DanielQ Ping Dou
Mar 6, 2007·Critical Reviews in Oncology/hematology·David J Stewart
Apr 26, 2007·Chemical Reviews·Yongwon Jung, Stephen J Lippard
May 23, 2007·Proceedings of the National Academy of Sciences of the United States of America·Bryan M O'NeillFloyd E Romesberg
Jul 13, 2007·Nature Reviews. Cancer·Lloyd Kelland
Feb 13, 2008·Cancer Metastasis Reviews·Xiongbin LuLawrence A Donehower
Jan 17, 2009·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Danielle D JandialStephen B Howell

❮ Previous
Next ❯

Citations

Jan 21, 2012·Canadian Journal of Microbiology·Silvia Rodríguez LombarderoM Esperanza Cerdán
Dec 24, 2014·Chemical Biology & Drug Design·Yi GouHong Liang
Apr 5, 2014·Spectrochimica Acta. Part A, Molecular and Biomolecular Spectroscopy·Mei LiHong Liang
Aug 30, 2012·Dalton Transactions : an International Journal of Inorganic Chemistry·Chun-Yan GaoShi-Ping Yan
Jan 21, 2014·Dalton Transactions : an International Journal of Inorganic Chemistry·Abeer A IbrahimHamed Karimian

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cell Checkpoints & Regulators

Cell cycle checkpoints are a series of complex checkpoint mechanisms that detect DNA abnormalities and ensure that DNA replication and repair are complete before cell division. They are primarily regulated by cyclins, cyclin-dependent kinases, and the anaphase-promoting complex/cyclosome. Here is the latest research.